Circio invites to corporate update webcast on 26 March 2025
- CEO Dr. Erik D Wiklund will provide a general company update and present the most recent circVec experimental data and R&D strategy
- CFO Dr. Lubor Gaal will present the 2024 financial results (unaudited) and provide an update on Circio´s corporate development activities
Oslo, Norway 19 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, invites to a live webcast at 10:00am CET on Wednesday 26 March 2025. In the webcast, Circio management will provide a corporate update and present the latest developments for the circVec platform technology.
The webcast will include an overview of ongoing testing with the novel circVec 3.0 generation, AAV and non-viral gene therapy vector development, and tissue-specific circVec expression data in vivo, as well as an outlook on experimental plans and milestones.
The corporate section will cover Circio´s 2024 financial results (unaudited) and provide an update on financing and business development activities for 2025.
Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal
Time: 10:00 CET on 26 March 2025
click here to access the Teams webcast
Meeting ID: 392 868 593 190
Passcode: Mn7uS2qQ
Participate by phone:
+47 21402155
Phone conference ID: 394 288 903#
Questions can be submitted in advance by email to Erik D Wiklund: [email protected] or directly in the live webcast
A recording of the webcast will be made available on the Circio webpage